ACUT:OTC-Accustem Sciences Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.388

Change

0.00 (0.00)%

Market Cap

USD 3.13M

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

N/A

USD 568.62B
CSLLY CSL Ltd

N/A

USD 89.31B
CMXHF CSL Limited

N/A

USD 89.27B
QSAM Qsam Biosciences Inc

N/A

USD 73.79B
UCBJY UCB SA ADR

N/A

USD 25.10B
UCBJF UCB SA

N/A

USD 25.05B
ARGNF argenx SE

N/A

USD 22.28B
GNMSF Genmab A/S

N/A

USD 19.00B
WXIBF WuXi Biologics

N/A

USD 8.40B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 7.75B

ETFs Containing ACUT

DESE:LSE 1.22 % 0.00 %

N/A

N/A
WTEC:F 1.22 % 0.00 %

N/A

N/A
WTEC:XETRA 1.22 % 0.00 %

N/A

N/A
DESD:LSE 0.90 % 0.00 %

N/A

N/A
EQLT 0.45 % 0.75 %

N/A

N/A
SMD 0.42 % 0.10 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -37.99% 26% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.99% 26% F 13% F
Trailing 12 Months  
Capital Gain -77.83% 20% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.83% 20% F 10% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.39% 53% F 51% F
Dividend Return 6.39% 53% F 46% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 58.48% 59% D- 45% F
Risk Adjusted Return 10.93% 60% D- 45% F
Market Capitalization 3.13M 37% F 28% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.